glp 1 approved for cardiovascular disease and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia The GLP-1 Revolution Continues
Description
GLP-1 based therapies led to statistically significant reductions in the serum levels of brain natriuretic peptide (40.16 [51.50, 28.81]
Optimum cellular metabolism
The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.
Diabetic patients prescribed tirzepatide, semaglutide, dulaglutide, and exenatide are less likely to be diagnosed with depression after starting the medication compared to those not on a glucagon-like peptide-1 receptor agonist (GLP-1) medication.
Hypothyroidism slows metabolism and makes weight loss harder, but GLP-1 receptor agonists like semaglutide can still be effective when thyroid hormone is optimized
Lose weight, not your mind all thanks to Ro.
